SAB Biotherapeutics, Inc. — Form SCHEDULE 13D/A
Filed August 10, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
RA Capital Management, L.P. (Boston-based investment firm) filed an amended Schedule 13D/A regarding beneficial ownership in SAB Biotherapeutics, Inc. (a publicly-traded biotech company with ~$76.7M market value). The filing was submitted on August 10, 2026, but the document provided does not include the substantive amendment details—specific shareholding percentages, share counts, dollar amounts of transactions, or what changed from the prior filing cannot be determined from the header/metadata alone.
Why this rating
Schedule 13D/A amendments are routine for significant shareholders; absent concrete details on ownership %, share counts, or transaction value, and given RA Capital's role as a financial investor rather than operational control change, this appears procedural. No material transaction specifics disclosed.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.